Inveresk Research, which went public on June 28, reported a 20 percent increase in revenue, to $55.5 million, for the second quarter.
Inveresk (Nasdaq: IRGI), a clinical research organization, also reported $50 million in one-time charges related to the public offering, including executive stock options. The company said its loss for the quarter was $37.9 million.
Inveresk went public at $13 a share and sank as low as $8.67 earlier this month before rallying. Its stock closed Monday at $11.80.